Because fat loss is often greater than lean mass loss, some people taking tirzepatide may end up with a higher percentage of their body weight coming from muscle after treatment
FDA Moves to Restrict Mass-Marketed Compounded GLP-1 Products The FDA announced plans to take action to restrict the use of glucagon-like peptide-1 (GLP-1) active pharmaceutical ingredients in nonFDA-approved compounded drugs that are being mass-marketed as alternatives to approved products, including those by companies such as Hims & Hers and certain compounding pharmacies
Please consult with your healthcare provider to see if this product may be a good fit for you
A COA may provide information about a tested sample, but equivalence to an approved drug also depends on formulation, concentration, excipients, device performance, sterility assurance, manufacturing controls, stability, pharmacokinetics, and regulatory review